BioCardia regains compliance with Nasdaq listing requirements

BioCardia (BCDA) has regained compliance with the Nasdaq Capital Market’s Listing Requirements. This confirmation follows the Company’s efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and advance its approved products. Specifically, on October 1, 2025, BioCardia received written notice from Nasdaq confirming that the Nasdaq Staff has determined the Company complies with Listing Rule 5550(b)(1). Accordingly, the Company’s securities will continue to be listed on the Nasdaq Capital Market under the symbol “BCDA.”